Blackhall FH - Search Results

1

Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.

Morrow CJ, Trapani F, Metcalf RL, Bertolini G, Hodgkinson CL, Khandelwal G, Kelly P, Galvin M, Carter L, Simpson KL, Williamson S, Wirth C, Simms N, Frankliln L, Frese KK, Rothwell DG, Nonaka D, Miller CJ, Brady G, Blackhall FH, Dive C. Morrow CJ, et al. Among authors: blackhall fh. Ann Oncol. 2016 Jun;27(6):1155-1160. doi: 10.1093/annonc/mdw122. Epub 2016 Mar 24. Ann Oncol. 2016. PMID: 27013395 Free PMC article.

2

Erlotinib in non-small cell lung cancer: a review.

Blackhall FH, Rehman S, Thatcher N. Blackhall FH, et al. Expert Opin Pharmacother. 2005 Jun;6(6):995-1002. doi: 10.1517/14656566.6.6.995. Expert Opin Pharmacother. 2005. PMID: 15952927 Review.

3

Where next for gefitinib in patients with lung cancer?

Blackhall F, Ranson M, Thatcher N. Blackhall F, et al. Lancet Oncol. 2006 Jun;7(6):499-507. doi: 10.1016/S1470-2045(06)70725-2. Lancet Oncol. 2006. PMID: 16750500 Review.

4

Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic.

Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Dean EJ, et al. Cancer Treat Rev. 2007 Apr;33(2):203-12. doi: 10.1016/j.ctrv.2006.11.002. Epub 2007 Jan 8. Cancer Treat Rev. 2007. PMID: 17210228 Review.

5

Small cell lung cancer and targeted therapies.

Blackhall FH, Shepherd FA. Blackhall FH, et al. Curr Opin Oncol. 2007 Mar;19(2):103-8. doi: 10.1097/CCO.0b013e328011bec3. Curr Opin Oncol. 2007. PMID: 17272981 Review.

6

X-linked inhibitor of apoptosis protein as a therapeutic target.

Dean EJ, Ranson M, Blackhall F, Dive C. Dean EJ, et al. Expert Opin Ther Targets. 2007 Nov;11(11):1459-71. doi: 10.1517/14728222.11.11.1459. Expert Opin Ther Targets. 2007. PMID: 18028010 Review.

7

Optimisation of circulating biomarkers of cell death for routine clinical use.

Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C. Greystoke A, et al. Ann Oncol. 2008 May;19(5):990-5. doi: 10.1093/annonc/mdn014. Epub 2008 Feb 27. Ann Oncol. 2008. PMID: 18304966 Free article.

8

Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment.

Bayman NA, Blackhall F, Jain P, Lee L, Thatcher N, Faivre-Finn C. Bayman NA, et al. Clin Lung Cancer. 2008 Mar;9(2):92-101. doi: 10.3816/CLC.2008.n.014. Clin Lung Cancer. 2008. PMID: 18501095 Review.

9

Radiotherapy for small-cell lung cancer-Where are we heading?

Bayman NA, Sheikh H, Kularatne B, Lorigan P, Blackhall F, Thatcher N, Faivre-Finn C. Bayman NA, et al. Lung Cancer. 2009 Mar;63(3):307-14. doi: 10.1016/j.lungcan.2008.06.013. Epub 2008 Aug 3. Lung Cancer. 2009. PMID: 18676057 Review.

10

Targeting blood vessels for the treatment of non-small cell lung cancer.

Amir E, Hughes S, Blackhall F, Thatcher N, Ostoros G, Timar J, Tovari J, Kovacs G, Dome B. Amir E, et al. Curr Cancer Drug Targets. 2008 Aug;8(5):392-403. doi: 10.2174/156800908785133187. Curr Cancer Drug Targets. 2008. PMID: 18690845 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters